Cormorant Asset Management »

Ascendis Pharma AS shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Ascendis Pharma AS (ASND) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Ascendis Pharma AS

Tip: Access up to 7 years of quarterly data

All positions including Ascendis Pharma AS held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ascendis Pharma AS by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $13M 50k 266.72

More positions owned by Cormorant Asset Management

Praxis Precision Medicines I Com New (PRAX)
Bridgebio Oncology Therapeut Com New (BBOT)
Parabilis Medicines
Rapport Therapeutics (RAPP)
Erasca (ERAS)
Edgewise Therapeutics (EWTX)
Eyepoint Com New (EYPT)
Alumis (ALMS)
Abivax Sa Sponsored Ads (ABVX)
Dianthus Therapeutics (DNTH)
Bright Minds Biosciences Com New (DRUG)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Bioage Labs (BIOA)
Oruka Therapeutics (ORKA)
Adlai Nortye Sponsored Ads (ANL)

View all positions for Cormorant Asset Management

Top funds holding Ascendis Pharma AS

RA Capital Management
venBio Select Advisor
Westfield Capital Management Company
Jupiter Topco
FMR
Artisan Partners Limited Partnership
BlackRock
Capital Research and Management Company - Division 3
Massachusetts Financial Services
Franklin Resources
Wellington Management Company
T. Rowe Price Associates
American Century Companies
Perceptive Advisors
Principal Financial Group

View all funds holding Ascendis Pharma AS